Retinoblastoma Cells
Retinoblastoma (Rb) is the most common primary intraocular malignancy in children, primarily driven by biallelic inactivation of the RB1 tumor suppressor gene. Our comprehensive collection of retinoblastoma cell lines provides essential models for studying the molecular pathogenesis, therapeutic vulnerabilities, and progression mechanisms of this pediatric cancer.
This portfolio includes both widely-used classic models like WERI-Rb-1 and the unique NCC-RbC series derived from Asian patient populations, offering a diverse genetic and phenotypic spectrum for both basic and translational research.
RB1-Profiled Pediatric Focus Diverse Models Validated
Key Features & Expertise
Our retinoblastoma cell lines are characterized to support research into pediatric ocular oncology
Diverse & Clinically Relevant Models
- Includes the classic, widely-studied WERI-Rb-1 cell line
- Features the unique NCC-RbC series, providing a panel of models from different genetic backgrounds
- Covers various disease stages and therapeutic contexts relevant to clinical management
Molecular & Genetic Characterization
- Documented RB1 gene status (mutations, deletions, methylation)
- Profiling of secondary genomic alterations (MYCN amplification, 1q/6p gains)
- Characterized for drug sensitivity to standard chemotherapies (carboplatin, etoposide, vincristine)
Authenticated for Pediatric Cancer Research
- STR-authenticated to ensure genetic identity crucial for reproducible research
- Rigorously tested and certified mycoplasma-free
- Supplied with detailed culture protocols optimized for retinoblastoma cell growth
FAQ
What is the difference between WERI-Rb-1 and the NCC-RbC cell lines?
WERI-Rb-1 is a long-established, widely used retinoblastoma cell line. The NCC-RbC series (e.g., NCC-RbC-51, -54, -59, etc.) represents a more recent collection of patient-derived models, offering a broader genetic diversity and potentially capturing a wider spectrum of the disease's heterogeneity, which can be valuable for translational studies.
Are all these cell lines derived from RB1-mutant tumors?
The vast majority of retinoblastomas are driven by biallelic inactivation of the RB1 gene. Our cell lines are characterized for their RB1 status. Some models may represent the rare RB1-wild type, MYCN-amplified subtype, which is important for studying this distinct and aggressive variant.
Which cell lines are suitable for studying chemotherapy resistance?
Multiple models in the collection, including various NCC-RbC lines, can be used to investigate intrinsic or acquired resistance to standard chemotherapeutic agents like carboplatin or topotecan. Comparative studies between sensitive and resistant pairs (if available) or panels with varying sensitivity profiles are recommended for resistance research.
Can these cell lines be used for in vivo orthotopic xenograft studies?
Yes, several retinoblastoma cell lines, particularly WERI-Rb-1 and some from the NCC-RbC series, are established for use in animal models. They can be injected intravitreally in immunodeficient mice to create orthotopic xenografts that mimic intraocular tumor growth, which is valuable for preclinical therapeutic testing.
What is the typical growth medium and conditions for these cells?
Most retinoblastoma cell lines are cultured in RPMI-1640 medium supplemented with 10-20% fetal bovine serum (FBS). They generally grow in suspension as floating aggregates or semi-adherent clusters. Detailed, cell line-specific protocols are provided with each shipment to ensure optimal culture conditions.
How are these pediatric cancer cell lines authenticated?
All cell lines undergo STR (Short Tandem Repeat) profiling to confirm their unique genetic identity. This is a critical quality control step, especially for rare pediatric cancer models, to prevent cross-contamination and ensure the validity of research findings. They are also certified mycoplasma-free.